- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full International Business Machines Ratings Report.
Pfizer will showcase third-quarter results, but investors will be more focused on the potential for its Inflectra drug, as well as its outlook on M&A.
The thwarted Medivation bidder lifts its full-year earnings estimates and announces a share buyback program.
Strong demand drives results and gains for Boeing, Akamai and others.
Britain's largest pharmaceuticals company reports growth in its HIV medicines business as it submits a shingles vaccine for FDA approval.